Y-Intercept (HK)’s Acumen Pharmaceuticals ABOS Stock Holding History

Y-Intercept (HK)’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-29,540	Closed	-$78.9K	–	1538
2026 Q2	$78.9K	Buy	+29,540	New	+$73K	﹤0.01%	1615
2025 Q3	–	Sell	-250,848	Closed	-$291K	–	1514
2025 Q2	$291K	Buy	+250,848	New	+$270K	0.01%	1368
2024 Q2	–	Sell	-37,191	Closed	-$151K	–	1328
2024 Q1	$151K	Buy	37,191 +17,843	+92%	+$67.2K	0.01%	1203
2023 Q4	$74.3K	Buy	+19,348	New	+$57.4K	0.01%	1133

Other funds holding ABOS

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Clune & Associates Chicago, Illinois $654M AUM 13.19% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Y-Intercept (HK)'s ABOS Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Acumen Pharmaceuticals (ABOS) in Q3 2026, closing a stake of 29,540 shares — an estimated $78.9K sold.

Y-Intercept (HK) first reported a position in ABOS in Q4 2023 and held it in 4 quarters. The position peaked at $291K in Q2 2025. 6 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

Y-Intercept (HK) reported no remaining Acumen Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 29,540 Acumen Pharmaceuticals shares in Q3 2026, an estimated $78.9K.
Y-Intercept (HK) first reported a position in Acumen Pharmaceuticals in Q4 2023 and held it in 4 quarters.
Y-Intercept (HK)'s Acumen Pharmaceuticals position peaked at $291K in Q2 2025.
6 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.